Mark Y Jeng

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 6

Top Topics

Acute Myeloid Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Blood Brain Barrier

Genome Wide Identification

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

American journal of hematology

The Journal of experimental medicine

Bone marrow transplantation

University of California San Francisco (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of California San Francisco Aug 15 2011 - Jul 01 2016

United States

PHD :: Biomedical Sciences

Publications

Mark Y Jeng, Helena Alexandra Yu
Leptomeningeal Metastasis in the Era of CNS-Penetrant Tyrosine Kinase Inhibitor Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Mark Y Jeng, Helena Alexandra Yu
Leptomeningeal Metastasis in the Era of CNS-Penetrant Tyrosine Kinase Inhibitor Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (23) (2024)
Mark Y Jeng, Helena Alexandra Yu
Leptomeningeal Metastasis in the Era of CNS-Penetrant Tyrosine Kinase Inhibitor Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (23) (2024)
Mark Y Jeng, Denice Kong, Raja Rajalingam, Richard J Lin, Rebecca L Olin
Lack of disease control remains a major barrier to transplant for older patients with AML. Bone marrow transplantation (2023)
Mark Y Jeng, Ritika Dutta, Irena T Tan, Tian Y Zhang, Gabriel N Mannis
Improved outcomes of octogenarians and nonagenarians with acute myeloid leukemia in the era of novel therapies. American journal of hematology 95 (11) (2020)
Mark Y Jeng, Philip A Hull, Mingjian Fei, Hye-Sook Kwon, Chia-Lin Tsou, Herbert G Kasler, Che-Ping Ng, David E Gordon, Jeffrey Johnson, Nevan Krogan, Eric Verdin, Melanie M Ott
Metabolic reprogramming of human CD8+ memory T cells through loss of SIRT1. The Journal of experimental medicine 215 (1) (2017)